Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-79032421 in Advanced Stage Solid Tumors
NCT06255665Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-79032421 in ovarian cancer, mesothelioma and pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Dose Limiting Toxicity at 21 days and Number of Participants with Adverse Events by Severity at 3 years. Started Feb 2024; status: completed.
02
Drugs
JNJ-79032421
03
Conditions
ovarian cancermesotheliomapancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06255665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06255665.